Cryo-EM is a technique that identifies the 3D structures of proteins; it can be used to determine how proteins function, how they malfunction in disease, and how best to target them with treatment therapies.

The two firms hope that combining cryo-EM with Charles River Laboratories' client support will speed drug discovery efforts, according to Charles River Laboratories.

Jackson Laboratory acquires Charles River Laboratories Japan
Biomedical research company the Jackson Laboratory has acquired Charles River Laboratories Japan's Research Models and Services business as a wholly owned...

Charles River reports 34% revenue spike in Q2
Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.

Charles River completes Vigene acquisition
Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction...

Charles River to acquire Vigene Biosciences for $293M
Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing...

Charles River Laboratories shows strong revenue, earnings gains in Q1
Sales gains across all three of its business segments helped drive Charles River Laboratories to a 16.6% increase in revenue in its 2021 first quarter.